Page 23 - Read Online
P. 23

Spallanzani et al. J Cancer Metastasis Treat 2018;4:28 I http://dx.doi.org/10.20517/2394-4722.2018.31                    Page 17 of 17

                   mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017;35 suppl 15:abstr520.
               89.  Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD. STAT3 signaling is required for optimal
                   regression of large established tumors in mice treated with anti-OX40 and TGFbeta receptor blockade. Cancer Immunol Res 2015;3:526-35.
               90.  Teufel M, Schwenke S, Seidel H, Beckmann G, Reischl J, Vonk R, Lenz HJ, Tabernero J, Siena S, Grothey A, Van Cutsem E, Jeffers
                   M, Wilhelm S, Wagner A, Laurent D, Kobina S, Rutstein MD, Wirapati P, Guinney J, Tejpar S. Molecular subtypes and outcomes in
                   regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. J Clin Oncol 2015;33 Suppl
                   15:abstr4000.
               91.  Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ,
                   Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi
                   Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-dependent MDSC infiltration
                   impairs tumor progression. Cancer Discov 2016;6:80-95.
   18   19   20   21   22   23   24   25   26   27   28